Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Real-time Quotes & News
Home
> Real-time Quotes & News
Real-time Quotes
Product
Bid
Ask
High
Low
Previous Close
{{ quote.symbol }}
{{ quote.bid }}
{{ quote.ask }}
High
{{ quote.high }}
Low
{{ quote.low }}
Previous Close
{{ quote.previousClose }}
*The above quotes are for reference only
Real-time News
2025-11-04
The European Commission: We will continue to work to restore the normal functioning of supply chains while safeguarding the EU's economic security.
The European Commission: We will continue to work to restore the normal functioning of supply chains while safeguarding the EU's economic security.
2025-11-04
US biotechnology company Metsera: The revised Pfizer (PFE.N) proposal requires partner companies to issue a statement indicating that "the Novo Nordisk (NVO.N) proposal is too risky and not feasible".
US biotechnology company Metsera: The revised Pfizer (PFE.N) proposal requires partner companies to issue a statement indicating that "the Novo Nordisk (NVO.N) proposal is too risky and not feasible".
2025-11-04
US biotechnology company Metsera: The merger agreement with Pfizer (PFE.N) remains in effect. Under the Pfizer merger agreement, Metsera and Pfizer can negotiate potential adjustments within two business days.
US biotechnology company Metsera: The merger agreement with Pfizer (PFE.N) remains in effect. Under the Pfizer merger agreement, Metsera and Pfizer can negotiate potential adjustments within two business days.
2025-11-04
US biotechnology company Metsera: Novo Nordisk (NVO.N)'s offer is better than Pfizer's (PFE.N) revised proposal, which values the company at up to $70 per share, totaling approximately $8.1 billion.
US biotechnology company Metsera: Novo Nordisk (NVO.N)'s offer is better than Pfizer's (PFE.N) revised proposal, which values the company at up to $70 per share, totaling approximately $8.1 billion.
2025-11-04
Novo Nordisk (NVO.N) has proposed valuing the U.S. biotechnology company Metsera at $86.20 per share, totaling $10 billion.
Novo Nordisk (NVO.N) has proposed valuing the U.S. biotechnology company Metsera at $86.20 per share, totaling $10 billion.
2025-11-04
U.S. biopharmaceutical company Metsera and Pfizer (PFE.N) may hold two days of talks regarding potential adjustments.
U.S. biopharmaceutical company Metsera and Pfizer (PFE.N) may hold two days of talks regarding potential adjustments.
1
...
16
17
18
19
20
...
117
Real-time Quotes
Real-time News
Chat with us
, powered by
LiveChat